Journal articleJAMA Oncol2018
Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial.
- Journal
- JAMA Oncol
- Published
- 1 July 2018
- Citations
- 436
- Type
- Article
These are bibliographic fields. A study card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try
Trials 6
- Builds on itFOLFIRINOX + RT for Pancreatic Cancer NCT01591733↗
- BackgroundNeoadjuvant vs Upfront Surgery for Resectable Pancreatic Cancer and Periampullary Cancer NCT07081360↗
- BackgroundmFOLFIRINOX With or Without Stereotactic Body Radiotherapy in Locally Advanced Pancreatic Adenocarcinoma NCT04986930↗
- BackgroundConcurrent FOLFIRINOX Plus High Intensity Focused Ultrasound for Pancreatic Cancer NCT05262452↗
- BackgroundIORT on Borderline Resectable Pancreatic Cancer NCT04090463↗
- BackgroundLosartan and Hypofractionated Rx After Chemo for Tx of Borderline Resectable or Locally Advanced Pancreatic Cancer NCT04106856↗